Bifidobacterium animalis subsp. Lactis and application thereof in regulating glycolipid metabolism and exercise ability

Through Bifidobacterium animalis subsp.lactis BAPerfectus006, the problem of single glycolipid metabolism intervention in the prior art is solved, poor safety and high-fat and high-sugar dietary multiple symptoms in response to insufficient response, and significantly reduced blood sugar and blood lipids. Improve glucose tolerance and exercise ability.

CN118909880AActive Publication Date: 2024-11-08完美(广东)日用品有限公司 +1

Patent Information

Application Number
CN202411239484.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-06-18
Filing Date
2024-09-05
Publication Date
2024-11-08
Estimated Expiration
2044-09-05

AI Technical Summary

Technical Problem

The prior art has problems such as single symptom intervention in regulating glycolipid metabolism, differences in safety and efficacy performance, failure to effectively deal with multiple symptoms under a high-fat and high-sugar diet, and no success in industrialization.

Method used

Bifidobacterium animalis subsp.lactis BAPerfectus006 is provided. Through strengthening culture medium and bioinformatic analysis, it is determined to be a safe strain, which has reduced glucose tolerance, relieved blood lipids and uric acid elevation, improved fatty liver, and inhibited The role of fat cells enlarge and enhance exercise ability.

Benefits of technology

Significantly reduce glucose, cholesterol, triglycerides and low-density lipoprotein cholesterol levels, improve glucose tolerance and fatty liver, inhibit fat cell hypertrophy, improve exercise endurance and liver glycogen storage capacity, and improve glycolipid metabolism than existing strains and the effect of athletic ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909880A_ABST
    Figure CN118909880A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of microorganisms, and particularly discloses bifidobacterium animalis subsp. Lactis and application thereof to regulation of glycolipid metabolism and athletic competence. According to the bifidobacterium animalis subsp. Lactis BAPerfecus006, healthy infant intestinal tracts are separated, no drug resistance, no hemolytic activity, no pathogenicity, no virulence genes and transferable drug-resistant genes are generated, and the bifidobacterium animalis subsp. Lactis BAPerfecus006 can be used for preparing the intestinal tracts of infants. The strain is a safe strain, is helpful for regulating glycolipid metabolism, has the effects of reducing sugar tolerance, relieving blood fat, increasing uric acid, increasing body weight, improving fatty liver, inhibiting adipocyte expansion and the like, and also has the effect of improving exercise ability. The strain has good probiotic characteristics and safety of probiotics, has remarkable in-vivo functions, and has great application potential and value in the aspect of developing products for regulating glycolipid metabolism, exercise ability and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of microbial technology, and in particular to an animal Bifidobacterium lactis subspecies and its application in regulating glucose and lipid metabolism and motility. Background Art

[0002] The current changes in dietary structure and excessive intake of high-energy diets such as high-fat and high-sugar foods have caused abnormal metabolism of fat and carbohydrates in the human body, which will cause a series of pathological and physiological changes in tissues or organs, often accompanied by obesity, elevated blood sugar, abnormal metabolism of triglycerides and cholesterol. In the long term, glucose metabolism will be impaired, and fat will accumulate on the blood vessel walls, causing vascular atherosclerosis, thereby increasing the risk of cardiovascular disease, fatty liver and other diseases, bringing significant economic and psychological burdens to patients. At present, clinical interventions are mostly carried out by synthetic drugs or lifestyle changes, but long-term drug treatment of abnormal glucose and lipid metabolism has many side effects and treatment limitations, and it is even more difficult to maintain long-term lifestyle changes. At the same time, those with metabolic abnormalities are mostly middle-aged and elderly people and obese people, and their exercise capacity is often limited.

[0003] In recent years, probiotics have been studied for intervention in metabolic abnormalities due to their high safety, among which Bifidobacterium animalis subsp. lactis is one of them.

[0004] For example, CN 114574407 B discloses Bifidobacterium lactis subsp. WKB99 and its application in the preparation of products for improving metabolic syndrome. Bifidobacterium lactis subsp. WKB99 can significantly reduce the serum glucose and cholesterol levels of high-fat mice and increase the high-density lipoprotein cholesterol content, but has no improvement on serum triglycerides and low-density lipoprotein cholesterol, and has not studied the improvement in body weight, fat cell enlargement, and uric acid. At the same time, the safety of this strain is not sufficient and has not been certified for industrialization.

[0005] CN 110604749 B discloses animal Bifidobacterium A12 and its application in controlling diabetes or hyperlipidemia, especially weight gain or obesity. Animal Bifidobacterium A12 can significantly reduce the serum insulin, glucose and leptin levels of mice fed a high-fat diet, increase the glucagon-like peptide-1 content, and protect the damaged pancreatic islets. The research mainly focuses on glucose metabolism and appetite.

[0006] At present, the research on animal bifidobacteria intervening in glucose and lipid metabolism is relatively single, focusing on one or two symptoms under high-fat diet, and failing to study the improvement of multiple symptoms under high-fat and high-sugar diet, and has not achieved success in industrialization and commercialization. In addition, the safety and beneficial properties of probiotics are different at the genus and species level. Probiotics of the same species and different strains also have differences in safety performance, efficacy performance and mechanism of action. Researching new probiotics that can regulate glucose and lipid metabolism is still a difficult point in current research.

[0007] Therefore, there is a need to continue researching probiotics with excellent ability to regulate glucose and lipid metabolism. Summary of the invention

[0008] The purpose of the present application is to overcome the deficiencies of the above-mentioned prior art and provide an animal bifidobacterium lactis subspecies and its application in regulating glucose and lipid metabolism and exercise capacity. The animal bifidobacterium lactis subspecies (Bifidobacterium animalis subsp. lactis) BAPerfectus006 provided in the present application helps to regulate glucose and lipid metabolism, has the effects of reducing glucose tolerance, relieving elevated blood lipids and uric acid, weight gain, improving fatty liver, inhibiting fat cell expansion, etc., and also has the effect of improving exercise capacity.

[0009] The present application provides an animal Bifidobacterium lactis subspecies, characterized in that the animal Bifidobacterium lactis subspecies is animal Bifidobacterium lactis subspecies (Bifidobacterium animalis subsp. lactis) BAPerfectus006, with a preservation number of GDMCC No: 62539, and a preservation classification name of Bifidobacterium animalis subsp. lactis. It was deposited in the Guangdong Provincial Microbiological Culture Collection Center on June 13, 2022, and the preservation address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0010] The animal Bifidobacterium lactis subspecies BAPerfectus006 of the present application is placed in a reinforced clostridial culture medium and anaerobically cultured at 37°C for 48 hours. The colonies are white, round, moist, opaque, with neat edges, irregular rod-shaped under a microscope, 0.6-0.9μm×1.1-4.8μm, arranged singly or in pairs, and Gram-positive.

[0011] The 16S rDNA gene sequence of the above-mentioned Bifidobacterium animalis subspecies lactis BAPerfectus006 is shown in SEQ ID NO:1, and the groEL gene sequence is shown in SEQ ID NO:2.

[0012] The 16S rDNA sequence and groEL gene sequence of Bifidobacterium animalis subsp. lactis BAPerfectus006 have a similarity of 100.0% with those of Bifidobacterium animalis subsp. lactis DSM 10140T (CP001606), and the similarity of groEL gene sequence with Bifidobacterium animalis subsp. animalis ATCC 25527T (CP002567) is 96.9%, so it can be determined to be Bifidobacterium animalis subsp. lactis.

[0013] The animal Bifidobacterium lactis subspecies BAPerfectus006 of the present application has no drug resistance, no hemolysis, no pathogenicity, no virulence genes and no transferable drug resistance genes. It is a safe strain that helps regulate sugar and lipid metabolism, has the effects of reducing glucose tolerance, alleviating increased blood lipids and uric acid, weight gain, improving fatty liver, inhibiting fat cell expansion, etc., and also has the effect of improving athletic ability.

[0014] The present application provides a specific molecular target for detecting the above-mentioned animal Bifidobacterium lactis subspecies, and the molecular target is:

[0015] (a) any one or more nucleotide sequences as shown in SEQ ID NO: 3; or,

[0016] (b) A nucleotide sequence in (a) in which one or more nucleotides are substituted, deleted or added and which has a nucleotide sequence with more than 90% homology with the nucleotide sequence in (a).

[0017] The present invention obtains the specific sequence of the above-mentioned animal Bifidobacterium lactis subspecies as SEQ ID NO: 3 through a bioinformatics analysis method, and performs specific verification on the sequence to determine that the specific sequence is a specific molecular target.

[0018] The present invention provides primers for detecting the specific molecular target, wherein:

[0019] The PCR primer set for amplifying the nucleotide sequence shown in SEQ ID NO:3 includes: an upstream primer shown in SEQ ID NO:4 and a downstream primer shown in SEQ ID NO:5;

[0020] The present application also provides a method for detecting the gene-specific molecular target of the above-mentioned animal Bifidobacterium lactis subspecies, comprising the following steps:

[0021] S1. Perform PCR amplification using the primer set (SEQ ID NO: 4 and SEQ ID NO: 5) shown in the gene-specific molecular target sequence SEQ ID NO: 3;

[0022] S2, performing gel electrophoresis to detect the amplified product;

[0023] S3. Observe whether the amplified product meets expectations;

[0024] The present application provides a use of a primer set for detecting a specific molecular target in preparing a detection reagent for Bifidobacterium animalis subsp. lactis BAPerfectus006, wherein the specific molecular target is a nucleotide sequence as shown in SEQ ID NO:3.

[0025] A bacterial agent is prepared by using the animal Bifidobacterium lactis subspecies BAPerfectus006.

[0026] As a preferred embodiment of the bacterial agent described in the present application, the number of live bacteria in the original powder of animal Bifidobacterium lactis subspecies BAPerfectus006 in the bacterial agent is ≥ 4×10 11 CFU / g.

[0027] Preferably, the method for preparing the bacterial powder comprises the following steps:

[0028] 1) activating animal Bifidobacterium lactis subspecies BAPerfectus006, and performing primary culture amplification and secondary culture amplification to obtain fermentation seed liquid;

[0029] 2) Centrifuge the fermented seed liquid, freeze-dry the bacterial sludge obtained by centrifugation to obtain bacterial powder.

[0030] Preferably, the abnormal glucose and lipid metabolism includes glucose and lipid metabolism disorder induced by a high-fat and high-fructose corn syrup diet.

[0031] After intervention with the animal Bifidobacterium lactis subspecies BAPerfectus006 of the present application, the glucose content decreased significantly (P < 0.0001), indicating that the strain has the effect of lowering blood sugar. Compared with the control strain, the effect is significantly different (P < 0.5), indicating that the hypoglycemic effect is better than the control strain HN019.

[0032] The present application also provides the use of the above-mentioned animal Bifidobacterium lactis subspecies in the preparation of products for regulating glucose and lipid metabolism and improving athletic ability.

[0033] As a preferred embodiment of the application described in the present application, the product includes the bacterial powder of the animal Bifidobacterium lactis subspecies BAPerfectus006.

[0034] As a preferred embodiment of the application described in the present application, the product is used in at least one of the following aspects: 1) lowering blood sugar; 2) improving glucose tolerance; 3) lowering serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol; 4) lowering the levels of total free fatty acids and saturated free fatty acids; 5) lowering uric acid; 6) improving fatty liver; 7) inhibiting fat cell enlargement; 8) improving exercise endurance.

[0035] Animal experiments show that compared with the high-fat and high-fructose syrup model group, intervention with Bifidobacterium animalis subsp. lactis BAPerfectus006 can improve the oral glucose tolerance (OGTT) of rats, and can also significantly reduce serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and total free fatty acids and saturated free fatty acids, especially palmitic acid and stearic acid (P<0.001), and blood uric acid levels are also improved; liver tissue pathological section analysis results show that the strain intervention can improve fatty liver, and adipose tissue pathological sections show that the proportion of fat cell hypertrophy is significantly reduced after intervention. This shows that Bifidobacterium animalis subsp. lactis BAPerfectus006 intervention is helpful for weight management, and has good lipid-lowering and glucose tolerance improvement functions. The animal Bifidobacterium lactis subsp. lactis BAPerfectus006 provided in the present application can also improve the endurance exercise time of mice, enhance the liver glycogen storage capacity, reduce the lactic acid content after exercise, and help improve exercise capacity.

[0036] Compared with the prior art, this application has the following beneficial effects:

[0037] The present application provides an animal Bifidobacterium lactis subspecies and its application in regulating glucose and lipid metabolism and motility. The animal Bifidobacterium lactis subspecies of the present application comes from the intestines of healthy infants, has no drug resistance, no hemolysis, no pathogenicity, no virulence genes and no transferable drug resistance genes, and is a safe strain. Model organism experiments show that it can significantly reduce glucose content, and the effect is better than the control strain. In vivo experiments show that it can significantly improve the glucose tolerance and dyslipidemia of rats with high-fat and high-fructose diet-induced sugar and lipid metabolism disorder models, and significantly reduce serum total cholesterol, triglycerides, low-density lipoprotein cholesterol, total free fatty acids, and saturated free fatty acids, especially the content of palmitic acid and stearic acid. It also has a significant effect on reducing blood uric acid. The results of liver tissue pathological section analysis show that the strain intervention can improve liver steatosis, and the adipose tissue pathological section shows that the proportion of fat cell hypertrophy is significantly reduced after intervention, indicating that animal Bifidobacterium lactis subspecies BAPerfectus006 intervention helps weight management. Compared with existing studies, its effect of improving sugar and lipid metabolism is better than existing related studies on animal Bifidobacterium, and it has the function of improving exercise endurance and functional recovery. The strain of the present invention has good probiotic properties and safety of probiotics, and has significant in vivo functions, and has great application potential and value in developing products such as regulating sugar and lipid metabolism and exercise capacity. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 This is the colony morphology of Bifidobacterium animalis subspecies lactis BAPerfectus006;

[0039] Figure 2 This is a microscopic bacterial morphology of animal Bifidobacterium lactis subspecies BAPerfectus006;

[0040] Figure 3 It is a 16s rDNA sequence alignment diagram of Bifidobacterium animalis lactis subspecies BAPerfectus006;

[0041] Figure 4 This is a comparison diagram of the groEL sequence of Bifidobacterium animalis subspecies lactis BAPerfectus006;

[0042] Figure 5 This is the complete chromosome sequence of the gene of Bifidobacterium animalis subspecies lactis BAPerfectus006;

[0043] Figure 6 is the amplification curve diagram of the real-time quantitative PCR using specific primers in Example 3;

[0044] Figure 7 It is the melting curve diagram of the real-time quantitative PCR of specific primers in Example 3;

[0045] Figure 8The electrophoresis diagram of the PCR amplification primers in Example 3;

[0046] Fig. 9 This is the hemolysis test diagram of animal Bifidobacterium lactis subspecies BAPerfectus006;

[0047] Fig.10 This is a graph showing the effect of animal Bifidobacterium lactis subspecies BAPerfectus006 on glucose content in hyperglycemic zebrafish;

[0048] Fig.11 This is the result diagram of the weight of rats in the glucose and lipid metabolism experiment before intervention;

[0049] Fig.12 This is a graph showing the effect of intervention with animal Bifidobacterium lactis subspecies BAPerfectus006 on oral glucose tolerance in rats;

[0050] Fig.13 This is a graph showing the effect of intervention with animal Bifidobacterium lactis subspecies BAPerfectus006 on lipid metabolism in rats;

[0051] Fig.14 This is a graph showing the effect of animal Bifidobacterium lactis subspecies BAPerfectus006 intervention on serum free fatty acids in rats;

[0052] Fig.15 This is a graph showing the effect of animal Bifidobacterium lactis subspecies BAPerfectus006 intervention on liver tissue pathology;

[0053] Fig.16 This is a graph showing the effect of animal Bifidobacterium lactis subspecies BAPerfectus006 intervention on the pathological morphology of subcutaneous fat and epididymal fat in rats;

[0054] Fig.17 Results of the experiment to evaluate the improvement of motor ability of animal Bifidobacterium lactis subspecies BAPerfectus006 in mice swimming to exhaustion without weight

[0055] (All data are expressed as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001,

[0056] ****P<0.0001). DETAILED DESCRIPTION

[0057] In order to better illustrate the purpose, technical solutions and advantages of the present application, the present application will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0058] In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.

[0059] Example 1. Isolation and Identification of Bifidobacterium animalis subsp. lactis BAPerfectus006

[0060] This embodiment provides a method for separating and identifying Bifidobacterium animalis subsp. lactis BAPerfectus006, comprising the following steps:

[0061] 1. Isolation of Bifidobacterium animalis subsp. lactis BAPerfectus006:

[0062] Feces of healthy male infants aged 3.5 months were collected as samples. 1 g of feces was added to 10 mL of sterile saline and mixed. The mixture was centrifuged at 800 rpm for 5 min to remove large impurities. 1 mL of the supernatant bacterial suspension was diluted 10 times with sterile saline and the appropriate dilution gradient (10 -5 , 10 -6 , 10 -7 ) was spread on a plate of Bifidobacterium culture medium BBL (Haibo Biotechnology Co., Ltd., Qingdao High-tech Industrial Park, HB0397) and placed in an anaerobic incubator (37°C) for 24 to 48 hours. White opaque circular colonies were selected with an inoculation loop and streaked 3-5 times continuously until a single colony was purified. Staining and microscopic examination were performed according to the instructions of the Gram staining kit. After confirming that it was a Gram-positive bacterium, it was sent for 16s rDNA sequencing and identification. After enrichment culture, the pure colonies were mixed with sterile glycerol (final concentration was 20% glycerol) and stored at -80°C.

[0063] 2. Identification of Bifidobacterium animalis subsp. lactis BAPerfectus006:

[0064] According to the "FMIC-QO01-001-2015 Microbiological Detection of Bacterial Multiphase Identification Detection Method", Bifidobacterium animalis subsp. lactis BAPerfectus006 was identified. The results are as follows:

[0065] (1) Morphological observation:

[0066] a. Macroscopic morphology: Bifidobacterium animalis subsp. lactis BAPerfectus006 was placed in a reinforced Clostridium medium and cultured anaerobically at 37°C for 48 hours. The colonies were white, round, moist, opaque, and had neat edges. Figure 1 .

[0067] b. Microscopic morphology: The bacteria are irregular rod-shaped under the microscope, 0.6-0.9μm×1.1-4.8μm, arranged singly or in pairs, and Gram-positive, such as Figure 2 .

[0068] (2) 16S rDNA identification and groEL sequence identification:

[0069] The 16S rDNA gene sequence of the strain claimed in the present application is shown in SEQ ID NO: 1.

[0070] The National Center for Biotechnology Information (NCBI) database was used for sequence alignment and phylogenetic analysis. Figure 3 From the results of 16S rDNA, it showed 100% similarity with Bifidobacterium animalis subsp. lactis DSM10140T (CP001606), and it was preliminarily determined to be Bifidobacterium animalis subsp. lactis.

[0071] In order to further confirm the accuracy of its type, its groEL sequence was tested, and the sequence result is shown in SEQ ID NO:2.

[0072] The groEL gene sequences were compared and the results were as follows Figure 4 As shown, the similarity between animal Bifidobacterium lactis subsp. BAPerfectus006 and animal Bifidobacterium lactis subsp. (Bifidobacterium animalis subsp. lactis) DSM10140T (CP001606) reached 100.0%, and the similarity between animal Bifidobacterium animalis subsp. (Bifidobacterium animalis subsp. animalis) ATCC 25527T (CP002567) was 96.9%, which can be determined to be animal Bifidobacterium lactis subsp.

[0073] Example 2: Whole genome sequencing of Bifidobacterium animalis subsp. lactis BAPerfectus006

[0074] Combining the second and third generation high-throughput gene sequencing technologies, the full gene sequence of Bifidobacterium animalis subsp. lactis BAPerfectus006 was detected, the whole genome map was drawn and the species was identified at the genome level.

[0075] After thawing the glycerol tube of Bifidobacterium animalis subsp. lactis BAPerfectus006 stored at -80°C, inoculate it into BBL medium, culture it anaerobically at 37°C for 24h, and after passage twice, take the bacterial culture in the logarithmic growth phase and place it in a sterile EP centrifuge tube for centrifugation. After centrifugation at 8000rpm for 5min (4°C), collect the bacterial cells, discard the supernatant, freeze them quickly in liquid nitrogen, wait for the bacterial cells to be frozen through, transfer them into a -80°C refrigerator, and mail them to the testing agency to complete the second and third generation sequencing. The second generation uses the DNBSEQ sequencing platform, and the third generation uses the Nanopore sequencing platform. The library construction and machine sequencing are carried out according to the library construction requirements of the sequencing platform. After the data is qualified after quality inspection and filtering, the third generation data is calibrated with the second generation data to complete the assembly of the bacterial genome map. The results showed that the genomic DNA of animal Bifidobacterium lactis subspecies BAPerfectus006 was circular, without plasmid, with a genome size of 1.93Mb and a GC content of 60.48%. A total of 9 ribosomal RNAs (rRNAs), 53 transfer RNAs (tRNAs), 1 small RNA (sRNA) and 1628 coding sequences (CDS) were detected. The whole genome map is shown in Figure 5 Based on the comparison of the obtained genome sequence with the recognized NT database, it was determined to be Bifidobacterium animalis subsp. lactis at the whole genome level.

[0076] The animal Bifidobacterium lactis subspecies obtained above was preserved, and the animal Bifidobacterium lactis subspecies was animal Bifidobacterium lactis subspecies (Bifidobacterium animalis subsp. lactis) BAPerfectus006, with a preservation number of GDMCC No: 62539, and a preservation classification name of Bifidobacterium animalis subsp. lactis. It was preserved in the Guangdong Provincial Microbiological Culture Collection Center on June 13, 2022, and the preservation address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0077] Example 3. Mining and verification of specific molecular targets of Bifidobacterium animalis subsp. lactis BAPerfectus006

[0078] 1. Mining of specific molecular targets of Bifidobacterium animalis subsp. lactis BAPerfectus006:

[0079] Bioinformatics analysis was performed on the data obtained in Example 2 in combination with the NCBI database, and a specific gene fragment (specific molecular target) of Bifidobacterium animalis subsp. lactis BAPerfectus006 was screened and obtained. The nucleotide sequence of the gene fragment is shown in SEQ ID NO:3.

[0080] 2. Validity detection of specific molecular target primers for Bifidobacterium animalis subsp. lactis BAPerfectus006:

[0081] A specific PCR amplification primer set was designed according to SEQ ID NO: 3, and the specific information is shown in Table 1.

[0082] Table 1 Primer sequences for PCR identification of characteristic molecular targets

[0083]

[0084] Real-time polymerase chain reaction (qPCR) was used to verify the specificity of the specific molecular target primers for identifying Bifidobacterium animalis subsp. lactis BAPerfectus006 and its potential for quantitative determination. The detection template was strain DNA, and DNA was extracted using the 2x Rapid Taq Master Mix extraction kit of Nanjing Novozyme Biotechnology Co., Ltd. according to the instructions.

[0085] The qPCR amplification reaction system and reaction conditions are as follows in Table 2:

[0086] Table 2 qPCR amplification reaction system and reaction conditions

[0087]

[0088] Amplification curve ( Figure 6 ) A plateau phase appears within 40 cycles, indicating that the amplification conditions are suitable; at the same time, the melting curve is as Figure 7 As shown, a single peak is presented without any mixed peaks, indicating that the primers have good specificity. The results show that this pair of primers can be used for the qualitative and quantitative determination of animal Bifidobacterium lactis subspecies BAPerfectus006.

[0089] 3. Specific verification of specific molecular targets of Bifidobacterium animalis subsp. lactis BAPerfectus006:

[0090] Polymerase Chain Reaction (PCR) and agarose electrophoresis were used to verify the specificity of the specific molecular target of Bifidobacterium animalis subsp. lactis BAPerfectus006, and the detection template was strain DNA. DNA was extracted using the 2x Rapid Taq Master Mix extraction kit of Nanjing Novozyme Biotechnology Co., Ltd., according to the instructions. The PCR reaction system and reaction conditions are as shown in Table 3:

[0091] Table 3 PCR reaction system and reaction conditions

[0092]

[0093] After PCR, 10 μl of PCR product was taken for 1.0% agarose electrophoresis to observe whether there was a single amplified band at the position corresponding to the product size of each primer set. If a single specific band can appear in the middle of the position corresponding to DNAMarker 300-400bp, and other non-target strains have no bands, then the SEQ ID NO:3 sequence is a specific molecular target of animal Bifidobacterium lactis subspecies. The strains used and the test results are shown in Table 4. In Table 4, "+" in the number column is the target strain, "-" is the negative control group without DNA template, and sequence numbers 1-19 are control strains, and "+" in the test result column indicates positive, and "-" indicates negative.

[0094] Table 4 Specific evaluation strains and results of Bifidobacterium animalis subspecies lactis BAPerfectus006

[0095]

[0096]

[0097] like Figure 8As shown in the PCR amplification product gel results: M is a DL1000 DNA standard marker. Except for the specific amplification product formed at about 327bp after the DNA of the target strain Bifidobacterium animalis subsp. lactis BAPerfectus006 was amplified by primers, no specific amplification product was formed in the control strain, indicating that only Bifidobacterium animalis subsp. lactis BAPerfectus006 contains a specific molecular target in this method. In summary, SEQ ID NO: 3 sequence can specifically identify Bifidobacterium animalis subsp. lactis BAPerfectus006.

[0098] Example 4: Verification of food safety of Bifidobacterium animalis subsp. lactis BAPerfectus006

[0099] 1. Drug sensitivity test:

[0100] The test was carried out according to the EU standard "EFSA 5206 Guidance on the characterization of miroorganisms used as feed additives or as production or ganisms-2.2". The results showed that animal Bifidobacterium lactis subspecies BA Perfectus 006 was sensitive to all antibiotics, as shown in Table 5.

[0101] Table 5 MIC values ​​and drug sensitivity test results of animal Bifidobacterium lactis subspecies BAPerfectus006

[0102] Types of antibiotics MIC breakpoint value (ug / mL) MIC measured value (ug / mL) result Ampicillin (AMP) 2 1.5 sensitive Chloramphenicol (CHL) 4 4 sensitive Clindamycin (CM) 1 0.50 sensitive Erythromycin (ERY) 1 0.50 sensitive Gentamycin (GM) 64 64 sensitive Streptomycin (SM) 128 96 sensitive Tetracycline (TE) 8 8 sensitive Vancomycin (VA) 2 0.50 sensitive

[0103] 2. Hemolytic test:

[0104] After puncture inoculation of blood plates, animal Bifidobacterium lactis subsp. BAPerfectus006 did not show a transparent circle around the puncture site, which was similar to the negative control bacteria Listeria innocua CICC 10417, while the positive control bacteria Staphylococcus aureus CICC 10473 showed a transparent circle around it, which was hemolytic ( Fig. 9 ). The test results showed that animal Bifidobacterium lactis subspecies BAPerfectus006 did not cause hemolysis and the result was negative.

[0105] 3. Bacterial pathogenicity test:

[0106] The bacterial pathogenicity test was carried out according to the method in Appendix A of the "Technical Guidelines for Safety Testing and Evaluation of Bacterial Species Used in Health Food Ingredients (2020 Edition)".

[0107] The results in Table 6 show that the bacterial suspension of animal Bifidobacterium lactis subspecies BAPerfectus006 was injected intraperitoneally once to mice of both sexes, and the amount of bacteria injected to each mouse was 1.04×10 7 CFU (bacterial concentration was 5.19×10 7 CFU / mL, injection volume was 0.2mL / animal). During the 21-day observation period, the animals were in normal condition, with no abnormal conditions such as poisoning signs and death.

[0108] Table 6 Results of bacterial pathogenicity test in mice (intraperitoneal injection)

[0109]

[0110] The results in Table 7 show that mice of both sexes were given oral administration of Bifidobacterium lactis subspecies BAPerfectus006 suspension for 3 consecutive days, with each oral administration dose of 5.08×10 9 CFU / (kg·BW) and 2.50×10 10 CFU / (kg·BW)(the concentration of bacterial suspension was 2.54×10 8 CFU / mL and 1.25×10 9 CFU / mL, the gavage volume was calculated based on the actual body weight of the mice as 20mL / (kg·BW)). During the 21-day observation period, the animals were in normal condition, with no abnormal conditions such as poisoning signs and death.

[0111] Table 7 Results of bacterial pathogenicity test in mice (oral gavage)

[0112]

[0113]

[0114] According to the bacterial pathogenicity test method for health food raw materials, the result of the bacterial pathogenicity test of animal Bifidobacterium lactis subspecies BAPerfectus006 was negative, indicating that animal Bifidobacterium lactis subspecies BAPerfectus006 showed no pathogenicity in animal experiments.

[0115] 4. Genome analysis of Bifidobacterium animalis subspecies BAPerfectus006:

[0116] The genome sequence measured in Example 2 is compared with the latest version of the internationally recognized antibiotic resistance gene database (CARD), and two resistance genes tetracycline antibiotics tet (W / N / W) and rifamycin antibiotics rpoB are annotated. These two potential resistance-related genes are also detected in the animal Bifidobacterium lactis subspecies BB12 genome. To assess the transfer risk of resistance genes, the two resistance genes annotated using NR database and software ABRicate, AMRFinderPlus, Phispy are further analyzed to see if there is a mobile genetic element (MGE), and the results are shown in Table 8, showing that these two genes do not have a transfer risk. Based on animal Bifidobacterium lactis subspecies BB12, it has been included in the "Infant Edible Bacteria List", and its safety has been effectively clinically verified. Rifamycin is not in the scope of antibacterial drugs specified in EFSA5206 and the drug sensitivity test of animal Bifidobacterium lactis subspecies BAPerfectus006 shows that it is sensitive to tetracycline, so it is believed that the antibiotic resistance of animal Bifidobacterium lactis subspecies BAPerfectus006 meets the edible safety requirements of health food.

[0117] Table 8 Results of risk assessment of drug resistance gene transfer in animal Bifidobacterium lactis subspecies BAPerfectus006

[0118]

[0119] The genome sequence measured in Example 2 was compared with the latest version of the virulence gene database (VFDB) and sorted by identity. The results of TOP15 are shown in Table 9. The highest homology between animal Bifidobacterium lactis subspecies BAPerfectus006 and the virulence gene DNA sequence is 72.6%, and no suspicious virulence gene (coverage>60% and similarity≥85%) was found. It does not contain plasmid at the same time, which reflects the stability and safety of the animal Bifidobacterium lactis subspecies BAPerfectus006 genome.

[0120] Table 9 Sequence alignment results of animal Bifidobacterium lactis subsp. BAPerfectus006 and virulence gene database

[0121]

[0122]

[0123] In summary, combined with the test results of drug sensitivity test, hemolysis test, mouse bacterial pathogenicity test, and virulence gene and resistance gene analysis, it can be seen that animal Bifidobacterium lactis subspecies BAPerfectus006 has no resistance to the antibiotics specified by EFSA5206, the hemolysis reaction is negative, the animal test is non-pathogenic, and the gene analysis shows no virulence gene and transferable resistance gene. In summary, animal Bifidobacterium lactis subspecies BAPerfectus006 is a safe strain that meets the safety requirements of humans.

[0124] Example 5. Preparation of Bifidobacterium animalis subsp. lactis BAPerfectus006 bacterial powder

[0125] This embodiment provides a method for preparing Bifidobacterium animalis subsp. lactis BAPerfectus006 bacterial powder, which is carried out with reference to Example 5 of patent CN117070423B, and comprises the following steps:

[0126] 1. Seed activation: Take one ampoule tube of Bifidobacterium animalis subsp. lactis BAPerfectus006 bacterial powder, resuscitate it, and then obtain fermentation seed liquid through primary culture amplification and secondary culture amplification.

[0127] 2. Fermentation culture: inoculate the fermentation seed liquid into a 5-ton fermentation tank filled with 2 tons of fermentation liquid and ferment at 37±2℃.

[0128] 3. Bacteria concentration: Start the centrifuge, and after the centrifuge runs stably, the material enters the centrifuge for centrifugal separation.

[0129] 4. Drying and crushing: freeze-dry the centrifugally concentrated bacterial sludge, and after drying, obtain the bacterial powder of Bifidobacterium animalis subsp. lactis BAPerfectus006. After production, the moisture content, water activity and viable count were tested, and the results are shown in Table 10.

[0130] Table 10 Animal Bifidobacterium lactis subspecies BAPerfectus006 bacterial powder production results

[0131] batch <![CDATA[Viable bacteria in bacterial powder (×10 11 CFU / g)]]> Moisture content (%) water activity 20220725001 5.6 7 0.12

[0132] In summary, Bifidobacterium animalis subsp. lactis BAPerfectus006 can be industrialized, which provides feasibility for realizing the use of the strain.

[0133] Example 6. Experiment on hypoglycemic effect of Bifidobacterium animalis subsp. lactis BAPerfectus006 on zebrafish

[0134] Experimental principle: Diabetes is a disease determined by genetics and related to environmental factors such as infection and obesity. Its basic pathology is a metabolic disorder caused by absolute or relative insulin deficiency. The morphogenesis, basic cell structure, and arrangement of the zebrafish pancreas are similar to those of mammals. The appetite regulation (such as serotonin) and insulin regulation functions are similar to those of humans. The development and function of other organ systems involved in glucose homeostasis (including brain, liver, adipose cell tissue, and skeletal muscle) are also similar to those of mammals. Zebrafish show persistent hyperglycemia under sugar load, and hyperglycemia can be induced in zebrafish in a high-sugar culture environment, simulating human type 2 diabetes.

[0135] Experimental groups:

[0136] (1) Blank group: containing zebrafish embryos and embryo culture medium, without modeling.

[0137] (2) Model group: containing zebrafish embryos and embryo culture medium, and high-glucose modeling.

[0138] (3) Positive drug group: zebrafish embryos were subjected to high glucose modeling and 24 μg / mL of metformin was added to the high glucose solution.

[0139] (4) Test group: Containing bacterial test substances and zebrafish embryos, high-sugar modeling was performed and bacterial cells were added to the high-sugar solution to make the bacterial concentration 2×10 7 CFU / mL. The bacterial powder obtained in Example 5 was diluted 10 times with PBS solution and centrifuged at 7000 rpm for 5 min at 4°C. The supernatant was discarded to obtain bacterial cells for testing. This experiment also used animal Bifidobacterium lactis subspecies HN019 for comparative testing.

[0140] The embryo culture medium is prepared as follows: NaCl 7.000g, NaHCO3 0.400g, KCl 0.100g, CaCl2 0.235g. Each reagent is added into a measuring cup in sequence according to the dosage of the formula, and the volume is made up to 2000mL with water that meets the requirements of GB / T 6682. The solution is filtered through a vacuum filter (pore size 0.2μM), sterilized in an autoclave, and kept at room temperature for use.

[0141] Experimental methods:

[0142] (1) 150 2dpf zebrafish embryos with normal development were pre-screened and randomly assigned to 6-well plates, 30 per well. The embryo culture medium in the 6-well plate was removed without harming the young fish. 3 mL of embryo culture medium was added to the normal control group, and 3 mL of high-glucose solution was added to the other groups for modeling for 2 days. After the modeling was completed, all group liquids were removed, and 3 mL of embryo nutrient solution was continued to be added to the blank group, 3 mL of high-glucose embryo nutrient solution with a concentration of 24 μg / mL metformin was added to the positive control group, and 3 mL of high-glucose embryo nutrient solution containing different concentrations of probiotic samples was added to the test substance. Incubate in the biochemical incubator for 2 days, replace 2 mL of solution every day during the incubation period, and perform blood glucose testing on zebrafish after the incubation (see Table 11 for specific dosing conditions).

[0143] Table 11 Treatment of test substances

[0144]

[0145] (2) Blood glucose measurement: After 2 days of incubation, remove the solution in the 6-well plate without harming the zebrafish. Rinse 2-3 times with embryo culture medium, take 18 zebrafish from each well, transfer 3 zebrafish into a 1.5 mL centrifuge tube, drain the liquid with a pipette, add 3 μL embryo culture medium, and homogenize. After homogenization, centrifuge at 4°C and 12000 rpm for 10 minutes. Take 1 μL of tissue supernatant and use a Roche blood glucose meter to test blood glucose according to the instrument manual.

[0146] (3) Data statistics: Experimental data were expressed as mean ± standard deviation (MeanSD). GraphPad Prism 10.1.1 software was used for statistical analysis and drawing. The differences between the two groups were compared using ordinary one-way analysis of variance. P < 0.05 was considered to be significantly different between the groups. The smaller the P value, the greater the significant difference between the groups. * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001, and **** represents P < 0.0001.

[0147] The results of the effect of animal Bifidobacterium lactis subspecies BAPerfectus006 on blood glucose levels in hyperglycemic zebrafish are as follows Fig.10As shown. Compared with the blank group, the glucose content of zebrafish in the model group increased significantly (P < 0.0001), indicating that the model was successfully established. After intervention with animal Bifidobacterium lactis subspecies BAPerfectus006, the glucose content decreased significantly (P < 0.0001), indicating that the strain has the effect of lowering blood sugar, while the glucose content of the control strain animal Bifidobacterium lactis subspecies HN019 intervention group did not show a significant decrease (P > 0.05), indicating that animal Bifidobacterium lactis subspecies BAPerfectus006 has the effect of lowering hyperglycemia and is superior to the control strain HN019.

[0148] Example 7: Experiment on the regulation of glucose and lipid metabolism in rats by Bifidobacterium animalis subsp. lactis BAPerfectus006

[0149] The bacterial powder obtained in Example 5 was used to evaluate the effect of animal Bifidobacterium lactis subspecies BAPerfectus006 on regulating glucose and lipid metabolism in rats.

[0150] Animal models and experimental methods:

[0151] 60 SPF male SD rats were weighed after 1 week of adaptive feeding (week 0). They were randomly divided into 2 groups, namely, a blank group (n=12) and a high-fat and high-sugar group (n=48). The normal group was given maintenance feed and sterilized water, and the model group was given a high-fat feed (D12492, ResearchDiets, USA) and fructose-glucose syrup water (F55, Guangdong Shuangqiao Co., Ltd.). Each group had free access to food and water. After 2 weeks, according to the weight gain, rats with small weight gain and resistance to high-fat feed and fructose-glucose syrup (about 20%) were eliminated, and finally 40 rats were left. Subsequently, they were randomly divided into 4 groups with 10 rats in each group, namely, a model group, a low-dose group of animal Bifidobacterium lactis subspecies BAPerfectus006 (BAP006 low), a medium-dose group of animal Bifidobacterium lactis subspecies BAPerfectus006 (BAP006 medium), and a high-dose group of animal Bifidobacterium lactis subspecies BAPerfectus006 (BAP006 high). At the same time, the rats with uneven weights were eliminated from the blank group, leaving only 10 rats.

[0152] The low, medium and high dose groups of animal Bifidobacterium lactis subspecies BAPerfectus006 were gavaged with bacterial powder of Example 5 (diluted with sterile saline), with doses of 0.0003g / (kg˙BW) (corresponding to a human intake of about 1.63 billion CFU / person / day), 0.0015g / (kg˙BW) (corresponding to a human intake of about 8.16 billion CFU / person / day), and 0.0075g / (kg˙BW) (corresponding to a human intake of about 40.8 billion CFU / person / day). During the intervention process, the low, medium and high dose groups of animal Bifidobacterium lactis subspecies BAPerfectus006 were gavaged with bacterial solution once a day, and the blank group and the model group were gavaged with saline once a day, with a volume of 2.5mL each time. The blank group continued to be given normal feed and drinking water, and the other groups were given high-fat feed and fructose syrup water for 8 weeks.

[0153] The references for rat to human dose conversion are as follows:

[0154] Huang Jihan, Huang Xiaohui, Chen Zhiyang, et al. Conversion of equivalent doses between animals and between animals and humans in pharmacological experiments[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, (09): 1069-1072.

[0155] During the experiment, the general survival conditions of the rats were observed and recorded, mainly including the mental state, movement, defecation and hair of the rats in each group. Feed and drinking water were changed every two days, and the food and water intake of the rats were recorded. The rats were weighed twice a week, and the intervention lasted for 8 weeks. On the first day of the eighth week of intervention, an oral glucose tolerance test (OGTT) was carried out. On the last day after the modeling, the body composition of the rats was determined using the Minispec LF90Ⅱ living animal body composition analyzer, including fat weight (Fat, g) and lean body weight (Lean, g), body fat rate = fat weight / body weight × 100%, lean body weight rate = lean body weight / body weight × 100%, and imaging materials of a single rat were collected for direct observation and comparison of the status. At the end of the experiment, after weighing and recording the data, 6% chloral hydrate was injected intraperitoneally at a dose of 0.5 mL / 100 g for anesthesia, and blood was collected from the abdominal aorta. The time of blood collection was recorded, and the blood was centrifuged after being placed at room temperature for two hours. The serum was collected, packaged, and frozen. The liver, epididymal fat (eWAT), and inguinal fat (iWAT) were dissected and removed (marked on the left and right sides, quickly rinsed with pre-cooled saline, and then quickly weighed and packaged. A portion of the tissue was fixed with paraformaldehyde for histopathological analysis, and the rest was quickly frozen in liquid nitrogen and stored at -80°C.

[0156] The experimental rats used in this experiment were 5-6 weeks old Sprague-Dawley (SD) healthy SPF male rats bred by Guangdong Medical Laboratory Animal Center [License No.: SCXK (Guangdong) 2022-0002]. The laboratory animal quality certificate number is No. 44007200107831; the animal experiment research plan was approved by the Experimental Animal Ethics Committee of Guangdong Pharmaceutical University (Project No.: SPF 2022011), and the experimental animals were kept in the SPF environment area of ​​Guangdong Pharmaceutical University Experimental Animal Center [License No.: SYXK (Guangdong) 2022-0125].

[0157] The experimental data were expressed as mean ± standard deviation (Mean ± SD). GraphPad Prism 10.1.1 software was used for statistical analysis and drawing. One-way analysis of variance was used to compare the differences between the two groups. P < 0.05 was considered to be significantly different between the groups (if there is no special mark, it was compared with the model group). The smaller the P value, the greater the significant difference between the groups. * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001, and **** represents P < 0.0001.

[0158] Experimental results:

[0159] 1. Impact on animal status:

[0160] During the experiment, the rats in the blank group maintained a good mental and behavioral state, with smooth fur and healthy milky white, and slightly moist ellipsoidal feces. After the rats in the model group consumed a high-fat, high-fructose syrup water diet, their movements became slower over time. Compared with the blank group, the rats were more likely to enter a quiet or sleepy state in a relatively noisy environment such as changing bedding or feed. The fur began to turn yellow and slightly dirty, and the feces were sticky and easy to deform or break. Compared with the model group, the behavior and mental state of the rats in the low, medium, and high dose intervention groups of animal Bifidobacterium lactis subspecies BAPerfectus006 were greatly improved, and they maintained a relatively good state under the same feeding environment, with slightly smooth fur and milky white, and slightly moist and formed feces.

[0161] 2. Impact on body weight:

[0162] After 2 weeks of high-fat and high-sugar diet and elimination of some obesity-resistant rats, the rats in the high-fat and high-sugar group were redivided into 4 groups: BAP006 low, BAP006 medium, BAP006 high, and model group. The body weights of the 4 groups of rats before administration of BAPerfectus006 were 335±14.3g, 334±16.6g, 336±21.5g, and 335±25.5g, respectively. There was no significant difference among the groups, and the body weights were basically the same ( Fig.11). This indicates that the body weights of rats in the high-fat and high-sugar groups were consistent when the animal Bifidobacterium lactis subspecies BAPerfectus006 was used for intervention, and the influence of body weight on the experimental results can be ruled out.

[0163] As shown in Table 12, after rats were fed with high-fat and high-fructose syrup water for 8 weeks, compared with the blank group, the weight gain and body fat rate of the model group were significantly increased (P < 0.001, P < 0.001), and the lean body mass rate was significantly reduced (P < 0.001), indicating that the model was successfully established; after 8 weeks of administration of animal Bifidobacterium lactis subspecies BAPerfectus006, compared with the model group, the weight gain of the animal Bifidobacterium lactis subspecies BAPerfectus006 intervention group showed a downward trend, especially after 4 weeks of intervention, the weight gain decreased significantly. In addition, the body fat rate showed a downward trend and the lean body mass showed an increasing trend after 8 weeks of intervention.

[0164] Table 12 Effects of Bifidobacterium lactis subsp. BAPerfectus006 intervention on body weight and body composition of rats

[0165] Blank Group Weight gain after 4 weeks of intervention, g Weight gain after 8 weeks of intervention, g Body fat percentage after 8 weeks of intervention, % Lean body mass rate after 8 weeks of intervention, % Blank Group 257±23*** 331±28*** 14.28±2.92*** 72.18±3.29*** Model Group 339±49 432±75 25.86±5.96 61.01±6.51 BAP006 Low 320±36 443±58 24.49±7.41 62.74±7.50 BAP006 305±28 429±33 22.38±5.53 64.99±5.55 BAP006 High 299±40 420±48 21.88±5.73 64.95±5.59

[0166] 3. Effect on oral glucose tolerance:

[0167] like Fig.12 As shown in the figure, after 8 weeks of feeding rats with high-fat and high-fructose syrup water, the oral glucose tolerance (OGTT) of the model group was significantly increased (1195) compared with the blank group (974) (P < 0.0001), indicating that the model was successfully established. After 8 weeks of administration of animal Bifidobacterium lactis subspecies BAPerfectus006, compared with the model group, the oral glucose tolerance (OGTT) of rats in the low, medium and high dose groups of animal Bifidobacterium lactis subspecies BAPerfectus006 were reduced to varying degrees, 1104, 1142, 1080, respectively, among which the high dose group had a significant improvement effect (P < 0.05), indicating that animal Bifidobacterium lactis subspecies BAPerfectus006 has the effect of improving the glucose tolerance of rats fed a high-fat and high-sugar diet.

[0168] 4. Impact on blood lipids:

[0169] The results are as follows Fig.13 As shown in a, after rats were fed with high-fat and high-fructose syrup water for 8 weeks, the serum triglyceride (TG) of the model group rats was significantly increased compared with the blank group (P < 0.0001). After 8 weeks of intervention with animal Bifidobacterium BAPerfectus006, the serum levels of the low, medium and high dose groups were reduced compared with the model group, among which the medium and high doses had significant reducing effects (P < 0.05, P < 0.01).

[0170] like Fig.13As shown in middle b, after rats were fed with high-fat and high-fructose syrup water for 8 weeks, the serum total cholesterol (TC) of rats in the model group was significantly increased compared with the blank group (P < 0.05). After 8 weeks of intervention with animal Bifidobacterium BAPerfectus006, the low, medium and high dose groups were significantly reduced compared with the model group (P < 0.001, P < 0.01, P < 0.05).

[0171] like Fig.13 Figure c shows that after 8 weeks of high-fat and high-fructose syrup feeding, the serum low-density lipoprotein cholesterol of the model group rats increased compared with the blank group (P=0.0758). After 8 weeks of intervention with animal Bifidobacterium BAPerfectus006, the serum low-density lipoprotein cholesterol of the low, medium and high dose groups were significantly reduced compared with the model group (P<0.01, P<0.001, P<0.05).

[0172] 5. Effect on serum free fatty acids:

[0173] like Fig.14 As shown in the results, after 8 weeks of feeding with high-fat and high-fructose syrup water, the serum total free fatty acids, total free saturated fatty acids, free stearic acid, and free palmitic acid of the rats in the model group were significantly increased (P < 0.0001); after 8 weeks of administration of the animal Bifidobacterium lactis subspecies BAPerfectus006 test substance, compared with the model group, the serum total free fatty acids and total saturated free fatty acids of the rats in the high-dose group were significantly decreased (P < 0.0001), especially the contents of palmitic acid and stearic acid (P < 0.0001).

[0174] 6. Impact on blood uric acid:

[0175] As shown in Table 13, after 8 weeks of feeding with high-fat and high-fructose syrup water, the serum low-density lipoprotein cholesterol of the rats in the model group was reduced compared with that in the blank group (P < 0.05); after 8 weeks of administration of the test substance of Bifidobacterium lactis subspecies BAPerfectus006, the blood uric acid (UA) levels of the rats in the Bifidobacterium lactis subspecies BAPerfectus006 intervention group were reduced compared with those in the model group.

[0176] Table 13 Effect of animal Bifidobacterium lactis subspecies BAPerfectus006 intervention on serum uric acid in rats

[0177] Group Blank Group Model Group BAP006 Low BAP006 BAP006 High Uric acid content, μmol / L 153±37* 219±86 178±47 189±42 194±40

[0178] 7. Effects on liver tissue pathology:

[0179] Typical rat liver tissue HE staining Fig.15As shown (microscope image magnified 200 times). Among them, the hepatocytes in the liver tissue of the rats in the control group were uniform in size, and the hepatocytes were arranged radially around the central vein, with a clear hepatic cord structure; most of the hepatocytes in the rats in the model group were enlarged, and large lipid droplet vacuoles appeared in the cytoplasm, or merged into larger lipid droplets; the cells were arranged in a disordered manner, and the hepatic cord structure was destroyed; while the hepatic cords of the rats in the high-dose group of animal Bifidobacterium lactis subspecies BAPerfectus006 were arranged regularly, and the fat vacuoles were significantly reduced.

[0180] 8. Impact on adipose tissue pathology:

[0181] 8. Impact on adipose tissue pathology:

[0182] Typical pathological sections of rat adipose tissue Fig.16 As shown in the figure, pathological sections show that the fat cells in the white adipose tissue (including epididymal fat eWAT and inguinal fat iWAT) of the model group rats began to swell, and the cell volume increased significantly; while the fat cells in the adipose tissue of the rats in the high-dose group of Bifidobacterium animalis subsp. lactis BAPerfectus006 significantly decreased, indicating that Bifidobacterium animalis subsp. lactis BAPerfectus006 has the effect of inhibiting the expansion of fat cells.

[0183] From the above animal experimental results, after 8 weeks of administration, animal Bifidobacterium lactis subspecies BAPerfectus006 can significantly improve the glucose tolerance and dyslipidemia of rats with glucose and lipid metabolism disorders induced by a high-fat and high-fructose syrup water diet, significantly reduce serum total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels, and significantly reduce serum total free fatty acids and saturated free fatty acids, especially palmitic acid and stearic acid. It also has a lowering effect on blood uric acid. At the same time, it can inhibit the increase of body weight and body fat rate, and increase the lean body mass rate. The results of liver tissue pathological section analysis show that the strain can improve fatty liver, and the adipose tissue pathological section shows that the proportion of fat cell hypertrophy is significantly reduced after intervention, indicating that animal Bifidobacterium lactis subspecies BAPerfectus006 intervention is helpful to regulate glucose and lipid metabolism, weight management, etc.

[0184] Example 8 Evaluation of Bifidobacterium animalis subsp. lactis BAPerfectus006 in improving exercise endurance

[0185] Experimental methods:

[0186] In this experiment, 4-week-old ICR inbred female mice (18-22g) were divided into a blank control group (24 mice), an animal Bifidobacterium lactis subsp. BAPerfectus006 intervention group (24 mice) (BAP006 group), and an oligofructose intervention group (8 mice). The above groups were fed with the same normal feed every day and gavaged once at regular intervals. The blank control group was gavaged with sterile saline, and the BAP006 group was gavaged with animal Bifidobacterium lactis subsp. BAPerfectus006 bacterial suspension (live bacteria dose of 1.03×10 10 CFU / (kg˙BW), the bacterial powder of Example 5 was dissolved in sterile saline), and the oligofructose group was gavaged with oligofructose solution (the dose was 3g / (kg˙BW, dissolved in sterile saline), and the gavage volume was calculated as 0.1mL / (10g˙BW), and the gavage was continued for 30 days.

[0187] After the last intragastric administration, the blank group and the BAP006 group were randomly divided into 3 groups (8 mice in each group), while the oligofructose intervention group was not divided into groups. The specific treatments were as follows:

[0188] (1) The first batch of blank group, the first batch of BAP006 group and oligofructose intervention group mice were subjected to weight-bearing swimming test: 30 minutes after the last administration of the test sample, the mice were placed in a swimming box with a lead sheet of 10% of their body weight at the base of their tails. The water depth was not less than 30 cm, and the water temperature was 25℃±1.0℃. The mice took more than 8 seconds from the start of swimming to the time when their mouths and noses began to sink to the water surface, which was the weight-bearing swimming exhaustion time of the mice.

[0189] (2) The second batch of blank group and the second batch of BAP006 group mice were subjected to a 90-min swimming experiment without weight bearing: 30 minutes after the last administration of the test sample, the mice swam in water at 30°C for 90 minutes. After resting for 60 minutes, the liver was removed and the liver glycogen content was detected.

[0190] (3) The third batch of mice in the blank group and the third batch of BAP006 group were swam in water at 30°C without weight for 10 minutes 30 minutes after the last sample administration. Blood was collected before and after swimming and 20 minutes after the end of swimming, and lactate was detected with a lactate meter. The area under the lactate curve was calculated.

[0191] The experimental data were expressed as mean ± standard deviation (Mean ± SD). GraphPad Prism 10.1.1 software was used for statistical analysis and drawing. The differences between the two groups were compared using independent sample t-test analysis. P < 0.05 was considered to be significantly different between the groups. The smaller the P value, the greater the significant difference between the groups. * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001, and **** represents P < 0.0001.

[0192] 1. Effects on the exhaustive time of weight-bearing swimming in mice:

[0193] The weighted swimming time can directly reflect the body's exercise endurance. The longer the weighted swimming time, the better the effect of the test substance. Fig.17 It can be seen that compared with the normal group, the weight-loaded swimming exhaustion time of mice in the animal Bifidobacterium lactis subspecies BAPerfectus006 intervention group was significantly prolonged (P<0.001), while there was no significant difference in the oligofructose intervention group, indicating that this strain can effectively improve the exercise endurance of mice, with the improvement effect exceeding 3 times, while the effect of oligofructose was not significant.

[0194] 2. Effects of unweighted swimming on lactic acid and glycogen content in mice:

[0195] When the body is in long-term high-intensity exercise, the lactic acid in the body will continue to increase, and the continuous accumulation will lead to a decline in exercise function, while the stored glycogen can provide energy for continuous exercise. Therefore, testing the lactic acid and glycogen content of mice at the same exercise intensity and the same rest time can reflect the mouse's ability to recover after exercise, and can also indirectly reflect the body's exercise endurance.

[0196] Table 14 Effects of animal Bifidobacterium lactis subspecies BAPerfectus006 intervention on liver glycogen and lactic acid in mice

[0197]

[0198] As can be seen from Table 14, compared with the normal group, the liver glycogen content of mice in the animal Bifidobacterium lactis subspecies BAPerfectus006 intervention group increased after normal swimming, indicating that the intake of this strain increased the energy reserves of mice and provided lasting energy to support continuous exercise. At the same time, it can significantly reduce the serum lactic acid content of mice after swimming (P < 0.01), indicating that this strain has a good effect in clearing the body's exercise metabolites.

[0199] In summary, animal Bifidobacterium lactis subspecies BAPerfectus006 can significantly improve glucose tolerance and dyslipidemia in rats with high-fat and high-fructose diet-induced glucose and lipid metabolism disorder model, significantly reduce serum total cholesterol, triglycerides, low-density lipoprotein cholesterol levels, as well as serum total free fatty acids and saturated free fatty acids, especially palmitic acid and stearic acid, reduce blood uric acid, inhibit the increase of body weight and body fat rate, increase lean body mass rate, improve liver steatosis, and reduce the proportion of fat cell hypertrophy, indicating that animal Bifidobacterium lactis subspecies BAPerfectus006 intervention is helpful in regulating glucose and lipid metabolism and weight management, and its hypoglycemic effect is better than that of the market strain animal Bifidobacterium lactis subspecies HN019. At the same time, animal Bifidobacterium lactis subspecies BAPerfectus006 has the effect of improving exercise capacity.

[0200] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present application rather than to limit the scope of protection of the present application. Although the present application has been described in detail with reference to the preferred embodiments, ordinary technicians in this field should understand that the technical solution of the present application can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present application.

Claims

1. An animal Bifidobacterium lactis subsp., characterized in that The animal Bifidobacterium lactis subspecies is animal Bifidobacterium lactis subspecies (Bifidobacterium animalis subsp. lactis) BAPerfectus006, with a preservation number of GDMCCNo: 62539. It was deposited in the Guangdong Provincial Microbiological Culture Collection Center on June 13, 2022, and the preservation address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

2. A specific molecular target for detecting the animal Bifidobacterium lactis subsp. lactis according to claim 1, characterized in that: The molecular targets are: (a) any one or more nucleotide sequences as shown in SEQ ID NO: 3; or, (b) A nucleotide sequence in (a) in which one or more nucleotides are substituted, deleted or added and which has a nucleotide sequence with more than 90% homology with the nucleotide sequence in (a).

3. A set of primers for detecting the specific molecular target as claimed in claim 2, characterized in that: The PCR primer set for amplifying the nucleotide sequence shown in SEQ ID NO:3 includes: an upstream primer shown in SEQ ID NO:4 and a downstream primer shown in SEQ ID NO:

5.

4. The method for detecting specific molecular targets of animal Bifidobacterium lactis subspecies according to claim 2, characterized in that: The following steps are involved: S1. Performing PCR amplification using a primer set for detecting a specific molecular target as shown in SEQ ID NO: 3; S2, performing gel electrophoresis to detect the amplified product; S3. Observe whether the amplified product meets expectations; The primer set for detecting the specific molecular target shown in SEQ ID NO: 3 includes a forward primer and a reverse primer; the forward primer is the nucleotide sequence shown in SEQ ID NO: 4; the reverse primer is the nucleotide sequence shown in SEQ ID NO:

5.

5. Use of a primer set for detecting specific molecular targets in the preparation of a detection reagent for Bifidobacterium animalis subsp. lactis BAPerfectus006, characterized in that: The specific molecular target is a nucleotide sequence as shown in SEQ ID NO:

3.

6. A bacterial agent, characterized in that: The bacterial agent is prepared using the Bifidobacterium animalis subsp. lactis BAPerfectus006 as claimed in claim 1.

7. The bacterial agent according to claim 6, characterized in that The number of live bacteria of the original powder of Bifidobacterium animalis subsp. lactis BAPerfectus006 in the bacterial agent is ≥4×10 11 CFU / g.

8. Use of the animal Bifidobacterium lactis subspecies as claimed in claim 1 in the preparation of products for regulating glucose and lipid metabolism and improving athletic ability.

9. The use according to claim 8, characterized in that The glucose and lipid metabolism includes glucose and lipid metabolism disorder induced by a high-fat and high-fructose corn syrup diet.

10. The use according to claim 8, characterized in that The product comprises bacterial powder containing Bifidobacterium animalis subsp. lactis BAPerfectus006 as claimed in claim 1.

11. The use according to claim 8, characterized in that The product is used in at least one of the following aspects: 1) lowering blood sugar; 2) improving glucose tolerance; 3) lowering serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol; 4) lowering the levels of total free fatty acids and saturated free fatty acids; 5) lowering uric acid; 6) improving fatty liver; 7) inhibiting fat cell expansion; and 8) improving exercise endurance.

Citation Information

Patent Citations

  • Bifidobacterium animalis A12 and its application in controlling diabetes or hyperlipidemia, especially weight gain or obesity.

    CN110604749B

  • Bifidobacterium animalis subsp. lactis WKB99 and its applications and products in the preparation of products for improving metabolic syndrome.

    CN114574407B

  • A strain of Lactobacillus plantarum LPPerfectus001 and its application

    CN117070423B

  • Bifidobacterium lactis strain B-622 and application thereof in preparation of medicine for treating diabetes

    CN114350547A

  • Application of bifidobacterium lactis SF-B21 in preparation of uric acid reducing product

    CN114668151A

Cited By

  • Application of bifidobacterium animalis subsp. Lactis ZYhyy-003 in preparation of pet product with hair beautifying effect

    CN119404940A

  • Bifidobacterium animalis subsp. Lactis and application thereof in exercise ability enhancing products

    CN121574885A

  • Bifidobacterium animalis lactis and its use in products for enhancing athletic performance

    CN121574885B